{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:33:35Z","timestamp":1790033615671,"version":"4.0.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFE0206400"],"award-info":[{"award-number":["2021YFE0206400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["226-2022-00220"],"award-info":[{"award-number":["226-2022-00220"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22373062"],"award-info":[{"award-number":["22373062"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204279"],"award-info":[{"award-number":["82204279"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Computers in Biology and Medicine"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.compbiomed.2023.107815","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T01:04:50Z","timestamp":1701911090000},"page":"107815","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Dissecting the role of ALK double mutations in drug resistance to lorlatinib with in-depth theoretical modeling and analysis"],"prefix":"10.1016","volume":"169","author":[{"given":"Xing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbo","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1210-3192","authenticated-orcid":false,"given":"Tianhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4102-1353","authenticated-orcid":false,"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingjun","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1152-7759","authenticated-orcid":false,"given":"Peichen","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.compbiomed.2023.107815_bib1","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.compbiomed.2023.107815_bib2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.compbiomed.2023.107815_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1082115","article-title":"Acquired ALK G1202R-, ALK I1171N-, or EML4-ALK-mediated resistance to ensartinib in lung adenocarcinoma but responded to lorlatinib: a case report","volume":"13","author":"Ye","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.compbiomed.2023.107815_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.808864","article-title":"Deciphering the mechanism of gilteritinib overcoming lorlatinib resistance to the double mutant I1171N\/F1174I in anaplastic lymphoma kinase","volume":"9","author":"Liang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.compbiomed.2023.107815_bib5","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1080\/15384047.2015.1095407","article-title":"Anaplastic lymphoma kinase: role in cancer and therapy perspective","volume":"16","author":"Zhao","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.compbiomed.2023.107815_bib6","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1042\/BJ20100609","article-title":"Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain","volume":"430","author":"Lee","year":"2010","journal-title":"Biochem. J."},{"key":"10.1016\/j.compbiomed.2023.107815_bib7","doi-asserted-by":"crossref","first-page":"10927","DOI":"10.1021\/acs.jmedchem.9b00446","article-title":"Drug discovery targeting anaplastic lymphoma kinase (ALK)","volume":"62","author":"Kong","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.compbiomed.2023.107815_bib8","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1021\/acscentsci.7b00419","article-title":"Combating drug-resistant mutants of anaplastic lymphoma kinase with potent and selective type-I1\/2 inhibitors by stabilizing unique DFG-shifted loop conformation","volume":"3","author":"Pan","year":"2017","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.compbiomed.2023.107815_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040699","article-title":"Current knowledge about mechanisms of drug resistance against ALK inhibitors in non-small cell lung cancer","volume":"13","author":"Smolle","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.compbiomed.2023.107815_bib10","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/cncr.34664","article-title":"Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: a systematic review and network meta-analysis","volume":"129","author":"Peng","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.compbiomed.2023.107815_bib11","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMoa1007478","article-title":"EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors","volume":"363","author":"Choi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.compbiomed.2023.107815_bib12","first-page":"1014","article-title":"Advances in drug resistance mechanisms and prognostic markers of targeted therapy in ALK-positive non-small cell lung cancer","volume":"23","author":"Wang","year":"2020","journal-title":"Zhongguo fei ai za zhi = Chinese journal of lung cancer"},{"key":"10.1016\/j.compbiomed.2023.107815_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100337","article-title":"Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients","volume":"7","author":"Hua","year":"2022","journal-title":"Esmo Open"},{"key":"10.1016\/j.compbiomed.2023.107815_bib14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ebiom.2015.12.009","article-title":"P-Glycoprotein mediates ceritinib resistance in anaplastic lymphoma kinase-rearranged non-small cell lung cancer","volume":"3","author":"Katayama","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.compbiomed.2023.107815_bib15","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/1759-7714.13299","article-title":"Overcoming resistance by ALK compound mutation (I1171S+G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer","volume":"11","author":"Takahashi","year":"2020","journal-title":"Thoracic Cancer"},{"key":"10.1016\/j.compbiomed.2023.107815_bib16","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1021\/jm500261q","volume":"57","author":"Johnson","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.compbiomed.2023.107815_bib17","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ebiom.2019.01.019","article-title":"Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance","volume":"41","author":"Okada","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.compbiomed.2023.107815_bib18","doi-asserted-by":"crossref","first-page":"25276","DOI":"10.1039\/C9CP04290C","article-title":"Importance of a crystalline water network in docking-based virtual screening: a case study of BRD4","volume":"21","author":"Zhong","year":"2019","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.compbiomed.2023.107815_bib19","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1021\/acs.jcim.5b00576","article-title":"Identification and preliminary SAR analysis of novel type-I inhibitors of TIE-2 via structure-based virtual screening and biological evaluation in in vitro models","volume":"55","author":"Pan","year":"2015","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.compbiomed.2023.107815_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202102435","article-title":"Discovery of novel GR ligands toward druggable GR antagonist conformations identified by MD simulations and markov state model analysis","volume":"9","author":"Hu","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.compbiomed.2023.107815_bib21","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/jm030644s","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening","volume":"47","author":"Halgren","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.compbiomed.2023.107815_bib22","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/prot.21123","article-title":"Comparison of multiple amber force fields and development of improved protein backbone parameters","volume":"65","author":"Hornak","year":"2006","journal-title":"Proteins: Struct., Funct., Bioinf."},{"key":"10.1016\/j.compbiomed.2023.107815_bib23","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and testing of a general amber force field","volume":"25","author":"Wang","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.compbiomed.2023.107815_bib24","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/jcc.20290","article-title":"The Amber biomolecular simulation programs","volume":"26","author":"Case","year":"2005","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.compbiomed.2023.107815_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-46825-1","article-title":"Molecular modeling of ALK L1198F and\/or G1202R mutations to determine differential crizotinib sensitivity","volume":"9","author":"Chuang","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.compbiomed.2023.107815_bib26","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/14756366.2022.2135511","article-title":"Binding selectivity-dependent molecular mechanism of inhibitors towards CDK2 and CDK6 investigated by multiple short molecular dynamics and free energy landscapes","volume":"38","author":"Wang","year":"2023","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.compbiomed.2023.107815_bib27","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1039\/D1CP04361G","article-title":"Binding mechanism of inhibitors to SARS-CoV-2 main protease deciphered by multiple replica molecular dynamics simulations","volume":"24","author":"Liang","year":"2022","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.compbiomed.2023.107815_bib28","doi-asserted-by":"crossref","first-page":"9478","DOI":"10.1021\/acs.chemrev.9b00055","article-title":"End-point binding free energy calculation with MM\/PBSA and MM\/GBSA: strategies and applications in drug design","volume":"119","author":"Wang","year":"2019","journal-title":"Chem. Rev."},{"key":"10.1016\/j.compbiomed.2023.107815_bib29","doi-asserted-by":"crossref","DOI":"10.1186\/s13321-022-00639-y","article-title":"Predicting the mutation effects of protein-ligand interactions via end-point binding free energy calculations: strategies and analyses","volume":"14","author":"Yu","year":"2022","journal-title":"J. Cheminf."},{"key":"10.1016\/j.compbiomed.2023.107815_bib30","doi-asserted-by":"crossref","first-page":"10135","DOI":"10.1039\/C9CP01674K","article-title":"Assessing the performance of MM\/PBSA and MM\/GBSA methods. 9. Prediction reliability of binding affinities and binding poses for protein-peptide complexes","volume":"21","author":"Weng","year":"2019","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.compbiomed.2023.107815_bib31","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/bioinformatics\/bty879","article-title":"farPPI: a webserver for accurate prediction of protein-ligand binding structures for small-molecule PPI inhibitors by MM\/PB(GB)SA methods","volume":"35","author":"Wang","year":"2019","journal-title":"Bioinformatics"},{"key":"10.1016\/j.compbiomed.2023.107815_bib32","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2174\/157340906778226454","article-title":"Recent advances in free energy calculations with a combination of molecular mechanics and continuum models","volume":"2","author":"Wang","year":"2006","journal-title":"Curr. Comput. Aided Drug Des."},{"key":"10.1016\/j.compbiomed.2023.107815_bib33","doi-asserted-by":"crossref","first-page":"18958","DOI":"10.1039\/C9CP04096J","article-title":"Assessing the performance of the MM\/PBSA and MM\/GBSA methods. 10. Impacts of enhanced sampling and variable dielectric model on protein-protein Interactions","volume":"21","author":"Wang","year":"2019","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.compbiomed.2023.107815_bib34","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbac127","article-title":"Characterizing the stabilization effects of stabilizers in protein-protein systems with end-point binding free energy calculations","volume":"23","author":"Tang","year":"2022","journal-title":"Briefings Bioinf."},{"key":"10.1016\/j.compbiomed.2023.107815_bib35","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1021\/ci400066x","article-title":"Molecular principle of topotecan resistance by topoisomerase I mutations through molecular modeling approaches","volume":"53","author":"Pan","year":"2013","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.compbiomed.2023.107815_bib36","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1021\/ci300375k","article-title":"Theoretical studies on the susceptibility of oseltamivir against variants of 2009 A\/H1N1 influenza neuraminidase","volume":"52","author":"Li","year":"2012","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.compbiomed.2023.107815_bib37","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.antiviral.2014.01.010","article-title":"The competitive binding between inhibitors and substrates of HCV NS3\/4A protease: a general mechanism of drug resistance","volume":"103","author":"Guan","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.compbiomed.2023.107815_bib38","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1021\/ar000033j","article-title":"Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models","volume":"33","author":"Kollman","year":"2000","journal-title":"Accounts Chem. Res."},{"key":"10.1016\/j.compbiomed.2023.107815_bib39","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/(SICI)1096-987X(19990130)20:2<217::AID-JCC4>3.0.CO;2-A","article-title":"Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO)","volume":"20","author":"Weiser","year":"1999","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.compbiomed.2023.107815_bib40","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1016\/j.apsb.2020.04.003","article-title":"Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension","volume":"10","author":"Yang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.compbiomed.2023.107815_bib41","first-page":"932","volume":"vol. 1","author":"Kaestner","year":"2011"},{"key":"10.1016\/j.compbiomed.2023.107815_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003316","article-title":"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers","volume":"4","author":"Katayama","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.compbiomed.2023.107815_bib43","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-11-2906","article-title":"Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer","volume":"18","author":"Doebele","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.compbiomed.2023.107815_bib44","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1215530","article-title":"Acquired resistance to crizotinib from a mutation in CD74-ROS1","volume":"368","author":"Awad","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.compbiomed.2023.107815_bib45","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.2147\/OTT.S293901","article-title":"Identification of novel alectinib-resistant ALK mutation G1202K with sensitization to lorlatinib: a case report and in silico structural modelling","volume":"14","author":"Yang","year":"2021","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.compbiomed.2023.107815_bib46","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.1002\/jcb.26666","article-title":"A molecular dynamics investigation into the mechanisms of alectinib resistance of three ALK mutants","volume":"119","author":"He","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.compbiomed.2023.107815_bib47","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2147\/DDDT.S147104","article-title":"Insight into resistance mechanism of anaplastic lymphoma kinase to alectinib and JH-VIII-157-02 caused by G1202R solvent front mutation","volume":"12","author":"Wang","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.compbiomed.2023.107815_bib48","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","article-title":"Targeting ALK: precision medicine takes on drug resistance","volume":"7","author":"Lin","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.compbiomed.2023.107815_bib49","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.1158\/1078-0432.CCR-14-1511","article-title":"Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib","volume":"20","author":"Katayama","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.compbiomed.2023.107815_bib50","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ccr.2011.04.004","article-title":"CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant","volume":"19","author":"Sakamoto","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.compbiomed.2023.107815_bib51","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1508887","article-title":"Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F","volume":"374","author":"Shaw","year":"2016","journal-title":"N. Engl. J. Med."}],"container-title":["Computers in Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010482523012805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010482523012805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:57:49Z","timestamp":1720573069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010482523012805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":51,"alternative-id":["S0010482523012805"],"URL":"https:\/\/doi.org\/10.1016\/j.compbiomed.2023.107815","relation":{},"ISSN":["0010-4825"],"issn-type":[{"value":"0010-4825","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dissecting the role of ALK double mutations in drug resistance to lorlatinib with in-depth theoretical modeling and analysis","name":"articletitle","label":"Article Title"},{"value":"Computers in Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.compbiomed.2023.107815","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107815"}}